Market & Competitive Landscape
Treatment landscape, standards of care, pipeline, competitors and emerging modalities
Better hemato-oncology strategies start with deeper market understanding
I support consulting firms, pharma and biotech companies in understanding hemato-oncology markets, generating actionable insights and translating them into asset and brand strategies that maximize commercial potential across Europe, with a particular focus on France.
Valentin PETIT – Independent consultant
Discuss a project
Complex markets make confident decisions harder
Hemato-oncology is evolving rapidly. New therapeutic modalities, expanding pipelines, shifting standards of care and increasingly complex treatment pathways continuously reshape market opportunities and competitive dynamics.
Navigating this environment requires more than data alone. It requires a deep understanding of the therapeutic area, its science, treatment landscape and clinical practices. It also requires the ability to understand how these dynamics translate into local market realities, from HCP behaviors and patient pathways to healthcare organization and competitive dynamics.
The challenge is not simply gathering more information. It is uncovering insights that are difficult to access, combining them with the available evidence, and identifying what truly matters. The real value comes from understanding what those insights mean and translating them into clear strategic implications for the asset, brand or market at hand.
How I can help
I support teams across the strategic journey, from market understanding to strategic execution
Understand - Market & Opportunity Assessment
Key questions
Where are the opportunities, unmet needs and competitive threats?
What could this market mean for our asset?
Objective
Build a clear view of the market landscape and its evolution to identify opportunities, anticipate threats and assess the commercial potential for your asset
Services
Market Opportunity Assessment
Epidemiology, addressable populations, patient segmentation, unmet needs and opportunity sizing
Patient Journey & Treatment Pathway Mapping
Diagnosis, treatment sequencing, referral patterns, patient flows and key decision points
Market Forecasting & Scenario Analysis
Patient-based forecasting, market evolution, competitive scenarios and commercial opportunity modelling
Discover - HCP & Market Insights
Key questions
What drives treatment decisions?
How is the asset perceived in the real world?
Objective
Generate actionable insights directly from the market to understand HCP behavior, treatment decisions and perceptions of your asset and its competitors
Services
Primary Market Research
Research design, discussion guides, HCP interviews, qualitative analysis and strategic synthesis
Treatment Decision Drivers & Barriers
Understand what shapes treatment choice, prescribing behavior and product perceptions
Concept, TPP & Value Proposition Testing
Test product profiles, concepts, positioning hypotheses and value propositions with relevant HCPs
Decide - Asset & Brand Strategy
Key questions
What do these insights mean for the considered asset or brand?
Where should the focus be?
How can we differentiate and maximize commercial potential?
Objective
Translate market and customer insights into clear strategic choices that strengthen positioning, differentiation and commercial potential
Services
Positioning & Differentiation Strategy
Define the product's strategic positioning and differentiation within an evolving treatment landscape
Asset & Brand Strategic Planning
Translate market insights into strategic priorities, objectives and initiatives for launch or established brands
Competitive Strategy & Scenario Planning
Anticipate competitor moves, evaluate market scenarios and define appropriate strategic responses
Implement - Strategy Execution & Implementation Support
Key questions
How to turn strategy into action?
How to support implementation and keep initiatives on track?
Objective
Turn strategic recommendations into concrete initiatives and provide flexible support to help teams move from planning to implementation
Services
Beyond-the-Pill Solution Design
Design practical initiatives addressing identified patient, HCP or treatment-pathway needs, including digital solutions
Implementation Roadmaps & Project Support
Structure implementation plans, milestones, responsibilities and provide hands-on workstream support
Performance Monitoring & Optimization
Define relevant KPIs, monitor implementation and market feedback, and identify opportunities for adjustment
Who I work with
Consulting Firms
Experienced, immediately deployable support for hemato-oncology engagements, from owning specific workstreams to reinforcing project teams with therapeutic-area expertise.
Pharma & Biotech Companies
Specialized support for strategic initiatives requiring deep hemato-oncology expertise, local market understanding or additional project capacity across France and Europe.
Investors
Independent hemato-oncology expertise to support asset evaluation, commercial due diligence and assessment of market opportunities, competitive landscapes and commercial potential.
Startups & Emerging Biotech Companies
Hands-on strategic support to understand European markets, validate opportunities and prepare market entry.
Why work with me?
I combine experience in life sciences strategy consulting, scientific and business training, and hands-on field experience in hemato-oncology.
Since 2020, I have worked on multiple hemato-oncology projects, supporting pharmaceutical companies on market strategy, launch preparation and commercial decision-making across multiple treatment modalities. This experience ultimately led me to co-found HarmonyCell, a digital Beyond-the-Pill solution aimed at improving access to CAR-T therapies in hematological malignancies.
6+ years in hemato-oncology
Experience across multiple therapeutic modalities, from conventional medicines to bispecific antibodies and CAR-T therapies
Strategy consulting for leading biopharma
Supported top global biopharma companies across consulting engagements, including market strategy, primary research, forecasting and launch-related projects
Bridging science and business
Combine scientific and business expertise to translate complex clinical topics into actionable market insights and strategic recommendations
30+ Hematologists engaged
Built first-hand knowledge of real-world hematology practice through direct engagement with 30+ hematologists, including patient pathways, clinical workflows and operational challenges
Selected Experience
Selected projects and examples across hemato-oncology strategy, insights and implementation.
Building a Beyond-the-Pill solution to improve CAR-T adoption in hemato-oncology
Building a Beyond-the-Pill solution to improve CAR-T adoption in hemato-oncology
- Challenge
- CAR-T pathways are complex and resource-intensive, requiring coordination across involved HCPs and pharmaceutical manufacturers. These operational constraints can increase HCP workload and limit treatment capacity, making the care pathway itself a potential barrier to broader CAR-T adoption.
- Approach
- We developed HarmonyCell, a proprietary digital platform designed to simplify and standardize CAR-T treatment pathways. The solution was informed by scientific and clinical guidance and refined through direct engagement with 30+ hematologists across French hematology departments.
- Impact
- We built a regulatory-compliant platform supporting referral, treatment planning, coordination and documentation across complex cell therapy pathways. Pilot testing indicated reduced administrative friction and improved care-team coordination, ultimately creating an incentive for CAR-T use and increasing treatment capacity through time and resource savings.
- Key learnings
- Key conditions for digital solutions to gain traction among HCPs include:
- Seamless integration into existing workflows
- A demonstrated and measurable value proposition
- Early involvement of clinical, IT and administrative stakeholders
Understanding treatment decision drivers to inform the positioning of a new DLBCL therapy
Understanding treatment decision drivers to inform the positioning of a new DLBCL therapy
- Challenge
- As the French DLBCL treatment landscape became increasingly complex, a leading pharmaceutical company needed to understand the real-world factors shaping hematologists’ treatment choices and identify where a new therapy could create meaningful differentiation and address remaining unmet needs.
- Approach
- I supported the design and execution of a targeted primary market research program, combining treatment landscape analysis with in-depth interviews with French hematologists to explore treatment decision drivers, perceptions of the TPP, unmet needs and expected future use.
- Impact
- The project generated actionable insights that helped clarify the asset’s differentiation, identify adoption drivers and barriers, and refine positioning, value messages and strategic priorities for the French launch. An example of such insights was the lack of clear standard of care for aged and unfit DLBCL patients.
- Key learning
- Deep therapeutic-area knowledge is critical to building credibility with hematologists during interviews, probing beyond the discussion guide and generating insights that go beyond what could be obtained through desk research alone.
Forecasting commercial scenarios for the international launch of a new multiple myeloma bispecific
Forecasting commercial scenarios for the international launch of a new multiple myeloma bispecific
- Challenge
- Ahead of launch, a leading pharmaceutical company needed to compare value-based agreement options and understand their financial implications across international markets.
- Approach
- I supported the development of a flexible Excel model combining patient-flow dynamics, clinical assumptions and contract mechanics. The tool accounted for different clinical outcomes and locally adaptable inputs, then translated multiple agreement structures into comparable revenue scenarios to support affiliate decision-making.
- Impact
- The model enabled more informed payer negotiation planning and standardized decision-making across markets while preserving local flexibility. It also supported faster and more sustainable patient access through value-based agreements balancing healthcare system affordability with commercially viable conditions for the pharmaceutical company.
- Key learning
- Robust modelling requires upfront alignment on clinical assumptions and contract logic, alongside a transparent, evidence-based and user-friendly design that local teams could use autonomously.
Have a hemato-oncology project in mind?
Whether you need support on a specific workstream or additional hemato-oncology expertise for a broader engagement, let's discuss how I can help.
Discuss a project